Component
Brain-parenchymal histidine after intravenous dosing
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Five minutes after intravenous histidine, Pht1-null mouse brain parenchyma contained 28-48 percent less tracer-associated histidine than wild type, despite comparable plasma time courses and no corresponding CSF difference.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_access
- Primary full text
- experimental_model
- Mouse knockout and intravenous pharmacokinetics.
- limitations
- Acute tracer distribution cannot define steady-state human brain deficiency.
- nutrient_topic
- L-Histidine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Histidine
- plain_language
- A normal circulating profile did not guarantee the same tissue exposure.
- primary_references
- A novel role for PHT1 in the disposition of l-histidine in brain: In vitro slice and in vivo pharmacokinetic studies in wildtype and Pht1 null mice. · 2017 · https://pubmed.ncbi.nlm.nih.gov/27845049/ · DOI 10.1016/j.bcp.2016.11.012
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
L-Histidine: supply, catabolism, histamine, receptors and cross-nutrient mechanisms (2026-09-19) · lines 98–104
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Mouse knockout and intravenous pharmacokinetics. · source_derived_draft · unverified_draft
## histidine-pht1-compartments A normal circulating profile did not guarantee the same tissue exposure. Five minutes after intravenous histidine, Pht1-null mouse brain parenchyma contained 28-48 percent less tracer-associated histidine than wild type, despite comparable plasma time courses and no corresponding CSF difference. Model: Mouse knockout and intravenous pharmacokinetics. Limitations: Acute tracer distribution cannot define steady-state human brain deficiency. Evidence access: Primary full text A novel role for PHT1 in the disposition of l-histidine in brain: In vitro slice and in vivo pharmacokinetic studies in wildtype and Pht1 null mice. · 2017 · https://pubmed.ncbi.nlm.nih.gov/27845049/ · DOI 10.1016/j.bcp.2016.11.012
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.